Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Bill Ackman and Scott Ferguson Are Investing In The Same Stocks

Page 1 of 2

At first glance, it doesn’t seem like fund managers Bill Ackman and Scott Ferguson are all that much alike. Except for the obvious facts that they are both Harvard graduates and both run billion-dollar hedge funds based in the Big Apple, the apparent similarities are few. However, when one takes a closer look, one can find a bunch of similarities between the mentor and his pupil, oh yes! Ferguson was the first man employed by Bill Ackman at his Pershing Square Capital Management LP, well before Ferguson left to spread his own wings with his own fund Sachem Head Capital Management. So let us take a closer look at the two hedge fund managers and find out what else they have in common, particularly when it comes to their stock picks. But first things first, Pershing Square Capital Management LP was founded in 2004 and keeps assets under management (AUM) of roughly $18.0 billion and a public equity portfolio of $14.97 billion. According to his latest 13F filing for the March 31 reporting period, Ackman’s public equity portfolio was nearly entirely devoted to three sectors: healthcare, materials, and transports. The much smaller Sachem Head Capital Management LP manages a public equity portfolio of $1.51 billion invested 78% in healthcare. So, did they have any picks in common? Indeed they did, and unsurprisingly, two of the biggest are in healthcare, in which both money managers are the most heavily invested. Let’s take a look at those stocks in this article, which are Zoetis Inc (NYSE:ZTS), Air Products & Chemicals, Inc. (NYSE:APD) and Allergan PLC (NYSE:AGN).


Why are we interested in the 13F filings of a select group of hedge funds? We use these filings to determine the top 15 small-cap stocks held by these elite funds based on 16 years of research that showed their top small-cap picks are much more profitable than both their large-cap stocks and the broader market as a whole; yet investors have been stuck (until now) investing in all of a hedge fund’s stocks: the good, the bad, and the ugly. Why pay fees to invest in both the best and worst ideas of a particular hedge fund when you can simply mimic the best ideas of the best fund managers on your own? These top small-cap stocks beat the S&P 500 Total Return Index by an average of nearly one percentage point per month in our backtests, which were conducted over the period of 1999 to 2012. Even better, since the beginning of forward testing at the end of August 2012, the strategy worked just as our research predicted and then some, outperforming the market every year and returning 142% over the last 33 months, which is more than 84 percentage points higher than the returns of the S&P 500 ETF (SPY) (see more details).

Bill Ackman
Bill Ackman
Pershing Square

Pharmaceutical company and former Pfizer Inc. (NYSE:PFE) subsidiary Zoetis Inc (NYSE:ZTS) has won the attention of the two hedge fund managers. Bill Ackman increased his stake by 1% to 41.82 million shares, while Scott Ferguson left his stake of 4.40 million shares untouched during the quarter. Zoetis Inc has so far during the spring been a wise pick, having increased by 17.3% on the exchange year-to-date and is also up by an impressive 55.5% during the last year. Zoetis Inc (NYSE:ZTS), founded in 1952, beat analysts’ expectations for the first quarter, posting earnings per share of $0.41 which was $0.04 above the estimates. Furthermore, the producer of drugs for pets and livestock announced earlier this year that it would now strive to increase its resource allocation and efficiency. A first step in that process is apparently the announcement that Zoetis Inc will cut 165 jobs at its headquarters during this year and next. It seems to us like John Segrich and Michael Molnar from Lorem Ipsum Management also don’t want to miss out on the opportunity in this stock, since they took a stake in Zoetis Inc (NYSE:ZTS) of 180,000 shares during the first quarter.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!